New Two-Drug combo tested against standard care for Tough-to-Treat blood cancer
NCT ID NCT06948084
Summary
This study is for adults with high-risk multiple myeloma, a blood cancer, that has either returned after initial treatment or stopped responding to it. It compares a new two-drug combination (daratumumab + teclistamab) against two standard three-drug combinations. The main goal is to see if the new combo is better at reducing cancer cells to undetectable levels after six months of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.